Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16

Benzinga Newsdesk www.benzinga.com Positive 82.2%

Neg 0% Neu 0% Pos 82.2%

Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $8 to $16.